Three Cases of Hemodialysis Patients with Advanced Gastric Cancer Treated with Paclitaxel and Nab-Paclitaxel
October 2014
in “
Annals of oncology
”
TLDR Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.
The document reports on three cases of hemodialysis patients with unresectable advanced or recurrent gastric cancer (URGC) who were treated with chemotherapy regimens involving paclitaxel and nab-paclitaxel. The first two cases, a 71-year-old man and a 64-year-old man, received paclitaxel on days 1, 8, and 15 of a 28-day cycle, experiencing adverse reactions such as Grade 2 anorexia, nausea, hair loss, and Grade 3 neutropenia and anemia, but no severe Grade 4 adverse events. Their liver metastases showed a partial response for over six months. The third case, a 62-year-old man, initially had a Grade 3 drug eruption from paclitaxel, likely due to the solvent used. He was switched to nab-paclitaxel, which did not cause a recurrence of the drug eruption. The conclusion drawn from these cases is that paclitaxel and nab-paclitaxel can be safe and effective for URGC patients on hemodialysis.